2. Search Result
Search Result
Results for "

PPAR-α/δ

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

3

Natural
Products

4

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114263
    NXT629
    3 Publications Verification

    		 PPAR Cancer
    NXT629 is a potent, selective, and competitive PPAR-α antagonist, with an IC50 of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC50s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively . NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models .
    NXT629
  • HY-13861
    GW7647
    15+ Cited Publications

    		 PPAR Cardiovascular Disease
    GW7647 is a potent PPARα agonist, with EC50s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.
    GW7647
  • HY-B0637
    Bezafibrate
    5+ Cited Publications

    BM15075

    		 PPAR Cardiovascular Disease Metabolic Disease
    Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate
  • HY-16995
    Pirinixic acid
    15+ Cited Publications

    Wy-14643

    		 PPAR Metabolic Disease Inflammation/Immunology
    Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.
    Pirinixic acid
  • HY-B0637S
    Bezafibrate-d6

    		PPAR Cardiovascular Disease Metabolic Disease
    Bezafibrate-d6 is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate-d6
  • HY-106278
    GW 590735

    		PPAR Metabolic Disease
    GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC50=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .
    GW 590735
  • HY-162123
    PPARα/δ agonist 2

    		PPAR Inflammation/Immunology
    PPARα/γ agonist 4 (compound 14) is a potent PPARα and PPARδ agonist with EC50s of 3255 nM and 1475 nM for human PPARα and PPARβ/δ, respectively. PPARα/γ agonist 4 shows anti-inflammatory effects .
    PPARα/δ agonist 2
  • HY-144111
    PPARα/δ agonist 1

    		PPAR Inflammation/Immunology
    PPARα/δ agonist 1 is a potent PPARα/PPARδ dual agonist (PPARα EC50=7.0 nM; PPARδ EC50=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC50=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .
    PPARα/δ agonist 1
  • HY-17618A
    Rac-Pemafibrate

    Rac-K13675

    		 PPAR Inflammation/Immunology
    Pemafibrate racemate (K13675 racemate) is the racemate of pemafibrate, and activates PPARα activity, with EC50s of 1 nM, >10 μM and 1.7 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.
    Rac-Pemafibrate
  • HY-B0637S1
    Bezafibrate-d4

    BM15075-d4

    		 Isotope-Labeled Compounds PPAR Cardiovascular Disease Metabolic Disease
    Bezafibrate-d4 is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate-d4
  • HY-B0637R
    Bezafibrate (Standard)

    		PPAR Cardiovascular Disease Metabolic Disease
    Bezafibrate (Standard) is the analytical standard of Bezafibrate. This product is intended for research and analytical applications. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate (Standard)
  • HY-N0234
    Bavachinin
    3 Publications Verification

    7-O-Methylbavachin; Bavachinin A

    		 Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology Cancer
    Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC50 value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .
    Bavachinin
  • HY-14817
    Indeglitazar

    PPM 204

    		 PPAR Metabolic Disease
    Indeglitazar (PPM 204) is an orally available PPAR pan-agonist for all three PPARα, PPARδ and PPARγ .
    Indeglitazar
  • HY-13928
    GW0742
    10+ Cited Publications

    GW610742

    		 PPAR Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
    GW0742
  • HY-119197
    PPARα/γ/δ agonist 1

    		PPAR Metabolic Disease
    PPARα/γ/δ agonist 1 (Compound 2) is a potent PPARα/γ/δ agonist, with an IC50 of 70 nM for PPARγ. PPARα/γ/δ agonist 1 can be used for the research of type 2 diabetes .
    PPARα/γ/δ agonist 1
  • HY-120886
    GW 2433

    		PPAR Metabolic Disease
    GW 2433 is a dual PPARα and PPARδ agonist. GW 2433 has the potential for the study of type II diabetes and dyslipidemia .
    GW 2433
  • HY-120255A
    17(S)-HDHA

    		PPAR Metabolic Disease
    17(S)-HDHA is a pro-resolving mediator (SPM). 17(S)-HDHA slightly activats PPARγ, PPARα and PPARδ .
    17(S)-HDHA
  • HY-N0234R
    Bavachinin (Standard)

    		Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC50 value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .
    Bavachinin (Standard)
  • HY-16578
    GW9662
    Maximum Cited Publications
    142 Publications Verification

    		 PPAR Cancer
    GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.
    GW9662
  • HY-121798
    TZD18

    		PPAR Metabolic Disease
    TZD18 is a potent and orally active PPARα and PPARγ dual agonist with IC50 values of 0.028, 0.057, >10 µM for PPARα, PPARγ, PPARδ, respectively. TZD18 reduces plasma levels of both glucose and triglycerides in diabetic mice. TZD18 has the potential for the research of type 2 diabetes .
    TZD18
  • HY-106266
    Chiglitazar

    Carfloglitazar

    		 PPAR Metabolic Disease
    Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC50s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.
    Chiglitazar
  • HY-19425
    NS-220

    		PPAR Metabolic Disease
    NS-220 is an orally active PPARα agonist with high subtype selectivity, with EC50 values of 1.9×10 -8 M, 9.6×10 -6 M and >10 -4 M for PPARα, PPAR γ and PPARδ, respectively. NS-220 is used in the research for hyperlipidemia or metabolic disorders in type-2 diabetes .
    NS-220
  • HY-B0760
    Fenofibric acid

    FNF acid

    		 PPAR COX Metabolic Disease
    Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.
    Fenofibric acid
  • HY-163547
    PPAR agonist 5

    		PPAR Inflammation/Immunology
    PPAR agonist 5 (compound 4b) is a potent PPAR agonist with EC50 values of 3.20, 1.51, 1.92 µM for PPARα, PPARβ/δ, PPARγ, respectively. PPAR agonist 5 shows anti-inflammatory effect .
    PPAR agonist 5
  • HY-112813
    TUG-1375
    3 Publications Verification

    		 Free Fatty Acid Receptor Metabolic Disease
    TUG-1375 is an agonist of free fatty acid receptor 2 (FFA2/GPR43), with a pKi of 6.69. TUG-1375 is inactive on FFA3, FFA4, PPARα, PPARγ, PPARδ, LXRα or LXRβ .
    TUG-1375
  • HY-16578S
    GW9662-d5

    		Isotope-Labeled Compounds PPAR Cancer
    GW9662-d5 is the deuterium labeled GW9662. GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively[1][2].
    GW9662-d5
  • HY-19522A
    Seladelpar sodium salt

    MBX-8025 sodium salt; RWJ-800025 sodium salt

    		 PPAR Metabolic Disease Inflammation/Immunology
    Seladelpar (MBX-8025) sodium salt is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar sodium salt shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar sodium salt hydrochloride can be used for the study of primary biliary cholangitis .
    Seladelpar sodium salt
  • HY-19522
    Seladelpar

    MBX-8025; RWJ-800025

    		 PPAR Metabolic Disease
    Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .
    Seladelpar
  • HY-N11722
    Panduratin A

    		PPAR Apoptosis Bacterial Infection Inflammation/Immunology Cancer
    Panduratin A, a natural chalcone compound, is a PPAR-α/δ activator. Panduratin A induces apoptosis, and promotes cell cycle arrest at G0/G1 phase in multiple hematologic malignant cell lines. Panduratin A has anticancer, antioxidant, anti-inflammatory, antibacterial, and antibiofilm activities .
    Panduratin A
  • HY-163443
    PPAR agonist 4

    		PPAR Others
    PPAR agonist 4 (Compound 12) is an orally active agonist for peroxisome proliferator-activated receptor (PPAR), which activates PPARα, PPARδ and PPARγ with EC50s of 0.7, 0.7 and 1.8 μM, respectively. PPAR agonist 4 exhibits anti-liver fibrosis efficacy .
    PPAR agonist 4
  • HY-19522B
    Seladelpar (lysine)

    MBX-8025 (lysine)

    		 PPAR Metabolic Disease
    Seladelpar (MBX-8025) lysine is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar lysine shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar lysine can be used for the study of primary biliary cholangitis .
    Seladelpar (lysine)
  • HY-B0760R
    Fenofibric acid (Standard)

    FNF acid (Standard)

    		 PPAR COX Metabolic Disease
    Fenofibric acid (Standard) is the analytical standard of Fenofibric acid. This product is intended for research and analytical applications. Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.
    Fenofibric acid (Standard)
  • HY-B0760S
    Fenofibric acid-d6

    		PPAR COX Metabolic Disease
    Fenofibric acid-d6 (FNF acid-d6) is the deuterium labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 µM, 1.47 µM, and 1.06 µM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.
    Fenofibric acid-d6
  • HY-Y1624
    1,1'-(Azodicarbonyl)-dipiperidine

    ADDP; SR 4077

    		 Free Fatty Acid Receptor PPAR Metabolic Disease
    1,1'-(Azodicarbonyl)-dipiperidine (ADDP) can be used in the condensation reaction of alcohols with acidic compounds. 1,1'-(Azodicarbonyl)-dipiperidine can also be used in the synthesis of GPR120 agonists with antidiabetic activity, as well as the synthesis of triple agonists for PPARα, PPARγ, and PPARδ. 1,1'-(Azodicarbonyl)-dipiperidine can be used in metabolic disease research .
    1,1'-(Azodicarbonyl)-dipiperidine
  • HY-155525
    Anti-NASH agent 1

    		PPAR Metabolic Disease Inflammation/Immunology
    Anti-NASH agent 1 (compound 3d)，a derivative of Elafibranor (HY-16737)，is a potent agonist of PPAR-α/δ，targeting to nonalcoholic steatohepatitis (NASH). Anti-NASH agent 1 (3-10 mg/kg; 4 weeks) improves hyperlipidemia，liver fat degeneration and liver inflammation in Methionine-choline deficiency (MCD) induced NASH mice model. Anti-NASH agent 1 shows low liver toxicity and potent liver protection effect .
    Anti-NASH agent 1
  • HY-19522C
    Seladelpar Lysine dihydrate

    MBX-8025 Lysine dihydrate; RWJ-800025 Lysine dihydrate

    		 PPAR Metabolic Disease
    Seladelpar (MBX-8025) Lysine dihydrate is the Lysine dihydrate salt form of Seladelpar (HY-19522). Seladelpar Lysine dihydrate is an orally active agonist for potent PPAR-δ, with EC50 of 2 nM. Seladelpar Lysine dihydrate shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar Lysine dihydrate can be used for the study of primary biliary cholangitis. Seladelpar Lysine dihydrate normalizes hyperglycemia, hyperinsulinemia, glucose, serum lipids and cholesterol levels, ameliorates the nonalcoholic steatohepatitis in mouse model .
    Seladelpar Lysine dihydrate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: